VENETOCLAX-BASED REGIMENS AFTER COVALENT BTKI EXPOSURE IN RELAPSED/REFRACTORY CLL: REAL WORLD OUTCOMES AND PREDICTORS OF SURVIVAL (SIE 2026) - Oct 6, 2026 - Abstract #DP138; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "The treatment paradigm of chronic lymphocytic leukemia (CLL) has shifted to targeted agents, including Bruton tyro- sine kinase inhibitors (BTKi) and venetoclax, creating a growing need for effective strategies in the post-BTKi sett- ing. The addition of rituximab is associated with improved survival, while progression on prior BTKi identifies a sub- group with inferior OS despite similar disease control, suggesting intrinsically high-risk biology. These findings sup- port a risk-adapted sequencing approach in the post-BTKi setting."
Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53
|
|
G. Bagnato1; A. Broccoli1; C. Pellegrini2; B. Casadei2; L. Argnani1; M. Carella1; G. Gugliotta2; S. Citro1; A. Desiderio1; M. Mutti1; N. Fabbri1; M. Gentilini1; G. Gabrielli1; C. Mazzoni1; F. D'Aniello1; F. Visini1; V. Stefoni1; P. L. Zinzani1
|